CannPal Research Abstract to be Published in Leading Veterinary Journal

KEY TAKEAWAYS:

• CannPal will be presenting on the Company’s Phase 1 trial results at the 2019 AVA (Australian Veterinary Association) Innovation, Research and Development Symposium in May
• The Innovation Symposium is a platform for industry and animal researchers to present their clinical research and findings directly to the veterinary profession;
• CannPal’s head of R&D, Dr Margaret Curtis will be presenting at the symposium and sharing the podium alongside speakers from world leading animal health companies such as Bayer, Ceva and Virbac;
• The abstract from the symposium will be published in the AVJ (Australian Veterinary Journal), Australia’s premier veterinary scientific journal.

Animal health company CannPal Animal Therapeutics Limited (ASX:CP1) (“CannPal” or “the Company”) is pleased to announce that CannPal will be presenting the results from the Company’s Phase 1 research at the 2019 AVA (Australian Veterinary Association) Innovation, Research and Development Symposium ahead of the AVA Conference at the Perth Convention Centre in May 2019.

Dr Margaret Curtis will present on the pharmacokinetic, safety, gene expression and inflammatory biomarker results from the Company’s robust randomised three group parallel pharmacokinetic study that was completed in 2018.

The AVA Conference in Perth is the largest veterinary conference in Australia, with an average of 1400 veterinary professionals expected to attend the conference between the 5th and 10th of May. The Innovation Symposium is being held on Sunday the 5th of May, with CannPal scheduled to present at 3:35pm.

Dr Curtis will be presenting alongside speakers from world leading animal health companies such as Bayer, Ceva and Virbac, and abstracts from the symposium will be published in the AVJ (Australian Veterinary Journal). The AVJ is Australia’s premier veterinary scientific journal, reaching an audience of over 5000 AVA members.

CannPal’s Head of Research and Development, Dr Margaret Curtis:

“This is a great opportunity to get our initial results out into the veterinary fraternity in Australia. The AVJ is widely read, and publication of this work will further disseminate the exciting results that CannPal is generating, bringing us closer to potentially approvable cannabis derived medicines for pets.”

CannPal’s Founder and Managing Director Layton Mills:

“Since founding the Company, CannPal has placed diligent focus on building a credible and experienced R&D team to complete robust and world leading research on the safety and efficacy of cannabis-derived compounds for Companion animals.

The AVA Symposium is an opportunity for CannPal to start sharing some of that research with the scientific and veterinary community, in the hopes of establishing CannPal as a clear leader in this field.”

About the AVA (Australian Veterinary Association)

The Australian Veterinary Association is a professional organisation that represents veterinarians across Australia, and seeks to facilitate collegiality and relationships within the veterinary profession across the Country. The AVA Innovation, Research and Development Symposium provides an opportunity for industry, university and other clinical veterinary researchers to share cutting edge information on the most recent veterinary research.

About CannPal Animal Therapeutics

CannPal Animal Therapeutics Limited (ASX: CP1) is a pharmaceutical-focused animal health Company researching the potential benefits of medical cannabis for companion animals. CannPal is researching and developing medicines derived from cannabinoids with the aim of providing veterinarians with clinically validated and standardised therapeutics to treat animals in a safe and ethical way.

CannPal has identified a significant potential opportunity to benefit from the rapidly growing medical cannabis and health markets by developing innovative therapeutics derived from the cannabis plant. The Company is working closely with regulatory authorities and veterinary research organisations conducting clinical trials with the aim of commercialising therapeutic products that will meet regulatory approval and support the health and well- being of companion animals.